Peptide YY Human

<strong>Peptide YY Human</strong>_x000D_ <strong>Catalog number:</strong> B2018969_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 4309.75 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> −20°C_x000D_ <strong>Keywords:</strong> Peptide yy human|118997-30-1|Peptide YY|Peptide YY [MI]|Peptide YY (human)|Peptide yy (1-36)|PYY (1-36) peptide|UNII-T2670C12I5|PYY(1-36)|T2670C12I5|Peptide YY, human|PYY|J-004037|Tyr-pro-ile-lys-pro-glu-ala-pro-gly-glu-asp-ala-ser-pro-glu-glu-leu-asn-arg_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21._x000D_ 2: Ji L, Jiang H, Cheng Z, Qiu W, Liao L, Zhang Y, Li X, Pang S, Zhang L, Chen L, Yang T, Li Y, Qu S, Wen J, Gu J, Deng H, Wang Y, Li L, Han-Zhang H, Ma Q, Qian L. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity Nat Commun. 2023 Dec 14;14(1):8289._x000D_ 3: Plut E, Calderón JC, Stanojlović V, Gattor AO, Höring C, Humphrys LJ, Konieczny A, Kerres S, Schubert M, Keller M, Cabrele C, Clark T, Reiser O. Stereochemistry-Driven Interactions of α,γ-Peptide Ligands with the Neuropeptide Y Y(4)-Receptor J Med Chem. 2023 Jul 27;66(14):9642-9657._x000D_ 4: Konieczny A, Braun D, Wifling D, Bernhardt G, Keller M. Oligopeptides as Neuropeptide Y Y(4) Receptor Ligands: Identification of a High-Affinity Tetrapeptide Agonist and a Hexapeptide Antagonist J Med Chem. 2020 Aug 13;63(15):8198-8215._x000D_ 5: Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B. Structural basis of ligand binding modes at the neuropeptide Y Y(1) receptor Nature. 2018 Apr;556(7702):520-524._x000D_ 6: Gleixner J, Gattor AO, Humphrys LJ, Brunner T, Keller M. [(3)H]UR-JG102-A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y(4) Receptor J Med Chem. 2023 Oct 12;66(19):13788-13808._x000D_ 7: Hyland NP, Sjöberg F, Tough IR, Herzog H, Cox HM. Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues Br J Pharmacol. 2003 Jun;139(4):863-71._x000D_ 8: Lafferty RA, Flatt PR, Irwin N. NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management? Peptides. 2024 Sep;179:171256._x000D_ 9: Schüß C, Behr V, Beck-Sickinger AG. Illuminating the neuropeptide Y(4) receptor and its ligand pancreatic polypeptide from a structural, functional, and therapeutic perspective Neuropeptides. 2024 Jun;105:102416._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/33449689">10: Milliken BT, Elfers C, Chepurny OG, Chichura KS, Sweet IR, Borner T, Hayes MR, De Jonghe BC, Holz GG, Roth CL, Doyle RP. Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis J Med Chem. 2021 Jan 28;64(2):1127-1138. </a>_x000D_ _x000D_ <strong>Products Related to Peptide YY Human can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>